Altoida develops digital neurological biomarkers for cognitive assessment in clinical trials using a tablet-based platform with augmented reality (AR). The platform measures cognitive and motor functions through multimodal data. Machine learning models called Digital Neuro Signatures (DNS) analyze features like micro-movements and reaction times. In 2021, Altoida’s predictive algorithm received FDA Breakthrough Device Designation for predicting the progression from Mild Cognitive Impairment (MCI) to Alzheimer’s disease. The platform aims for rapid and accurate assessments of neurological conditions and is intended for investigational use only. Altoida complies with SOC 2 Type II and ISO 27001 standards.